Survey of ophthalmology最新文献_第9页

Understanding healthcare communication in age-related macular degeneration care: A mixed-methods review of patients’ perspectives 了解老年黄斑变性护理中的医疗沟通：以混合方法回顾患者的观点。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-16 DOI: 10.1016/j.survophthal.2024.03.002

Mariska Scheffer , Juliane Menting , Hennie Boeije , Ruth van Nispen , Sandra van Dulmen

{"title":"Understanding healthcare communication in age-related macular degeneration care: A mixed-methods review of patients’ perspectives","authors":"Mariska Scheffer , Juliane Menting , Hennie Boeije , Ruth van Nispen , Sandra van Dulmen","doi":"10.1016/j.survophthal.2024.03.002","DOIUrl":"10.1016/j.survophthal.2024.03.002","url":null,"abstract":"<div><p>Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment among people aged 50 years and older. Earlier research has indicated that the communication process between patients and healthcare professionals (HCPs) leaves considerable room for improvement in AMD care. Effective communication is essential to enhance trust in the professional and understanding of the diagnosis and treatment, and decrease anxiety and stress related to illness. We review patients’ experiences, needs and preferences regarding information provision, communication style of the HCP and shared decision-making. We conducted a systematic search in PubMed, Embase, PsycINFO, CINAHL and Web of Science. Study quality was assessed using standard checklists of quality measures. Our search returned 31 eligible articles. Findings indicated current deficits in information provision for people with AMD. Patients were often ill-informed regarding the chronic character of the condition, treatment duration, nutrition, and visual aids and low vision rehabilitation. Many patients were not actively involved during the decision-making process. Altogether, patients with AMD are faced with challenges in terms of patient-HCP communication. Methods of providing information and discussing possible options for care need to be further investigated and improved for this patient group.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":"69 4","pages":"Pages 646-660"},"PeriodicalIF":5.1,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625724000183/pdfft?md5=de4b58e9b73c0ab6eefe5c5a258f3ba9&pid=1-s2.0-S0039625724000183-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review of economic evaluation of artificial intelligence-based screening for eye diseases: From possibility to reality 基于人工智能的眼病筛查经济评估系统回顾：从可能性到现实性。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-15 DOI: 10.1016/j.survophthal.2024.03.008

Hongkang Wu , Kai Jin , Chee Chew Yip , Victor Koh , Juan Ye

引用次数: 0

Clinical therapeutics for proliferative vitreoretinopathy in retinal detachment 视网膜脱离中增殖性玻璃体视网膜病变的临床疗法。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-15 DOI: 10.1016/j.survophthal.2024.03.007

Francesco Sabatino , Philip Banerjee , Mahiul M. K. Muqit

{"title":"Clinical therapeutics for proliferative vitreoretinopathy in retinal detachment","authors":"Francesco Sabatino , Philip Banerjee , Mahiul M. K. Muqit","doi":"10.1016/j.survophthal.2024.03.007","DOIUrl":"10.1016/j.survophthal.2024.03.007","url":null,"abstract":"<div><p>Proliferative vitreoretinopathy (PVR) is an abnormal and prolonged healing response to retinal injury (retinal detachment, post retinal detachment surgery) characterised by: pre/subretinal membrane formation; retinal gliosis and retinal shortening, retinal pigment epithelium cell proliferation; and increased glial (mainly Mu¨ller cells), fibroblast and inflammatory cell (macrophage, lymphocyte) activity, leading to tractional retinal holes/breaks and multiple costly eye operations suffered by patients. PVR can cause retinal re-detachment following primary surgical intervention for rhegmatogenous retinal detachment. Vitrectomy and scleral buckling surgery are the main approaches for treating PVR complications of retinal detachment. Patients require many operations to remove the scar tissue but vision results are suboptimal, and do not meet patient expectations. Over the past 40 years, this has been one of the greatest challenges for vitreoretinal surgeons and patients. Despite previous large clinical trials of multiple candidate drug therapeutics, no proven adjunctive treatment currently exists to either prevent, reduce, or treat PVR formation in retinal detachment. Both cellular proliferation and the intraocular inflammatory response are realistic targets for adjunctive treatments in PVR. The cellular components of PVR periretinal membranes (retinal pigment epithelial, glial, inflammatory and fibroblastic cells) proliferate and are thus targets for antiproliferative agents. In recent years, several new therapeutics have been tested, and we present an updated review of the clinical therapeutics for PVR in retinal detachment.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":"69 4","pages":"Pages 508-520"},"PeriodicalIF":5.1,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140140855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current management options for the treatment of refractory postoperative cystoid macular edema: A systematic review 目前治疗难治性术后囊样黄斑水肿的方法：系统综述。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-14 DOI: 10.1016/j.survophthal.2024.03.005

Layla J. Bunjo , Stephen Bacchi , James Pietris , Weng Onn Chan

引用次数: 0

Clinical outcome measures in vision and eye care 视力和眼科护理的临床结果测量。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-13 DOI: 10.1016/j.survophthal.2024.03.006

Luke Leidy , Anna Dickinson , Pradeep Ramulu , Joshua Ehrlich , Mona A. Kaleem

引用次数: 0

Medication-associated orbital inflammation: A systematic review 药物相关眼眶炎症：系统综述。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-13 DOI: 10.1016/j.survophthal.2024.03.003

Terence Ang MBBS , Viraj Chaggar , Jessica Y. Tong FRANZCO , Dinesh Selva DHSc FRANZCO FRACS

{"title":"Medication-associated orbital inflammation: A systematic review","authors":"Terence Ang MBBS , Viraj Chaggar , Jessica Y. Tong FRANZCO , Dinesh Selva DHSc FRANZCO FRACS","doi":"10.1016/j.survophthal.2024.03.003","DOIUrl":"10.1016/j.survophthal.2024.03.003","url":null,"abstract":"<div><p>We performed a comprehensive systematic review to identify medication-associated orbital inflammation and to characterize its clinico-radiological features. We reviewed English-language articles describing medication-associated orbital inflammation (i.e., orbital myositis, dacryoadenitis and orbital fat) published to June, 2023. Isolated inflammation of the intraocular structures or globe alone (i.e. uveitis, scleritis, optic neuritis and perineuritis) were excluded. In medication-associated orbital inflammation, the extraocular muscles are preferentially affected, occurring in isolation or in combination with other orbital and/or intraocular structures. Clinico-radiological manifestations may be non-specific; however, certain medications may be distinguished according to the presence of systemic prodrome, laterality, associated intraocular inflammation, and predisposition to involve certain orbital structures. Rapid identification, discontinuation of the provoking medication, and systemic corticosteroid therapy (if appropriate) typically achieves a favorable visual prognosis. As new medications become adopted by clinicians, rare adverse effects will be further delineated.Medication-associated orbital inflammation is an important diagnostic consideration in orbital inflammatory disease. A careful medication history and clinical assessment may be revealing, permitting timely discontinuation of the offending agent and initiation of appropriate management.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":"69 4","pages":"Pages 622-631"},"PeriodicalIF":5.1,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039625724000201/pdfft?md5=fa20309de7d4dc0ecb51ae16a8b32310&pid=1-s2.0-S0039625724000201-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New developments in the management of persistent corneal epithelial defects 治疗持续性角膜上皮缺损的新进展

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-01 DOI: 10.1016/j.survophthal.2023.07.005

María García-Lorente MD, Marina Rodríguez-Calvo-de-Mora MD PhD, José-María Sánchez-González OD PhD, Davide Borroni MD PhD, Francisco Zamorano-Martín MD, Carlos Rocha-de-Lossada MD PhD

引用次数: 0

Surgical and anesthetic influences of the oculocardiac reflex in adults and children during strabismus surgery 斜视手术中成人和儿童眼心反射的手术和麻醉影响。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-01 DOI: 10.1016/j.survophthal.2023.06.005

Robert W. Arnold MD

引用次数: 0

Ocular surface toxicities associated with modern anticancer therapies 与现代抗癌疗法相关的眼部表面毒性。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-01 DOI: 10.1016/j.survophthal.2023.10.002

Rafael Boucher MD , Oscar Haigh PhD , Emmanuel Barreau MD , Stéphane Champiat MD, PhD , Olivier Lambotte MD, PhD , Clovis Adam MD , Marc Labetoulle MD, PhD , Antoine Rousseau MD, PhD

{"title":"Ocular surface toxicities associated with modern anticancer therapies","authors":"Rafael Boucher MD , Oscar Haigh PhD , Emmanuel Barreau MD , Stéphane Champiat MD, PhD , Olivier Lambotte MD, PhD , Clovis Adam MD , Marc Labetoulle MD, PhD , Antoine Rousseau MD, PhD","doi":"10.1016/j.survophthal.2023.10.002","DOIUrl":"10.1016/j.survophthal.2023.10.002","url":null,"abstract":"<div><p><span><span><span><span>Cancer treatments have recently shifted from broad-spectrum </span>cytotoxic therapies to more focused treatments, maximizing anticancerous activity while reducing toxicity to healthy cells. These modern </span>anticancer therapies (MATs) encompass a wide range of innovative molecules that include </span>immune checkpoint inhibitors<span><span> and other targeted anticancer therapies, comprising antibody drug conjugates<span> and inhibitors of signal transduction. Some MATs are associated with </span></span>ocular surface<span> adverse events that can cause severe discomfort and even lead to loss of vision. While these complications remain rare, they are probably underreported. It is likely that both oncologists and ophthalmologists will come across MATs-associated ocular surface-adverse events in their practices, owing to the increasing number of patients being treated with MATs. Rapid identification of ocular surface-adverse events is crucial, as early intervention can manage these conditions to avoid vision loss and reduce negative impacts on </span></span></span>quality of life. We discuss characteristics of ocular surface pathologies attributed to MATs, describe the suspected underlying pathophysiological mechanisms, and outline the main lines of treatment.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":"69 2","pages":"Pages 198-210"},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Future directions in managing aniridia-associated keratopathy” [Surv Ophthalmol 68 (2023) 940–956] aniridia相关角膜病管理的未来方向"[Surv Ophthalmol 68 (2023) 940-956]的更正。

IF 5.1 2区医学

Survey of ophthalmology Pub Date : 2024-03-01 DOI: 10.1016/j.survophthal.2024.01.001

Arianne J.H. van Velthoven , Tor P. Utheim , Maria Notara , Dominique Bremond-Gignac , Francisco C. Figueiredo , Heli Skottman , Daniel Aberdam , Julie T. Daniels , Giulio Ferrari , Christina Grupcheva , Carina Koppen , Mohit Parekh , Thomas Ritter , Vito Romano , Stefano Ferrari , Claus Cursiefen , Neil Lagali , Vanessa L.S. LaPointe , Mor M. Dickman

引用次数: 0